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FOREWORD 
The dogma of adult neural stability who, until recently, reported the 
uniqueness of the brain in its lack of ability to repair itself once it had 
maturated to adulthood (Ramon y Cajal, 1969), had influenced the 
view of neurobiological research as well as the clinical research and 
the accepted methods for treating brain illnesses. This dogma has 
been progressively challenge by the discovery of the ability of 
certain areas of the adult brain (e.g., the hippocampus) to occur 
structural changes, including the generation of new neurons  and 
other brain cells and connections between and among neurons, a 
process known as adult neurogenesis. Animal studies demonstrated 
for the first time this ability of  adult brain, reporting data on rats 
(Altman and colleagues, 1960s and 1970s) , on birds (Goldman and 
Nottebohm, 1980s) and later in nonhuman primates. Human 
evidences came from studies conducted in the 1990s (Eriksson et al., 
1998). Besides, the neural plasticity, structural, synaptic and 
morphological, has been proposed like another critical neuronal 
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function playing an important role in the appropriate adaptative 
responses to environmental stimuli (Duman, 2004). Structural brain 
changes  (atrophy and cell loss of limbic structures) demonstrating in 
postmortem and neuroimaging studies have been represented the 
neurobiological basis of stress-related illnesses and contributed to the  
neurotrophic hypothesis of mood disorders, that could include 
alterations in brain structure and neural plasticity (Duman et al., 
1997). The maladaptive neurobiological changes occurring in 
depression (atrophy of limbic brain structures, decreased dendrite 
length and branching, and impaired neurogenesis) and impaired 
neuroplasticity are fundamental for the development of pathology.  
Investigations into the neurobiology of mood disorder have 
traditionally focused on the monoamine neurotransmitters to 
elucidate that depression is caused by decreased monoamine function 
in the brain (Hindmarch, 2002). However, even though 
monoaminergic antidepressants are generally used for first-line 
treatment, they do not exert their clinical benefit immediately and for 
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some people they do not provide any benefit at all. The time lag 
between the start of and response to antidepressants in patients whose 
symptoms improve can be explained by the effects of these drugs on 
brain-derived neurotrophic factor  (BDNF) and other growth-
regulating systems. Decreased BDNF expression can have serious 
consequences for the function of limbic structures that control mood 
and cognition and carry out reduced neurogenesis and atrophy of 
neurons. The effects of these drugs on neuroplasticity are particularly 
relevant given that treatment, increasing BDNF levels, may reverse 
or even prevent structural brain abnormalities. Research about the 
role of neurotrophic factors in neuropsychiatric disorders, efforting 
to define new treatment strategies to treat severe mood disorders and 
prevent the underlying disease progression, has already led to a 
number of innovative targets for therapeutic intervention. For 
example, BDNF has been administered intrathecally in amyotrophic 
lateral sclerosis or decreasing neurogenesis may be beneficial in 
some disorders, such as epilepsy (Stein et al., 2008). 
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INTRODUCTION 
 
Major depressive disorder: socio-epidemiologic and clinical 
background 
 
Depressive disorder is highly prevalent and affects about 15% of the 
population at some point in their lives (in United States the 12-month 
and lifetime prevalences of major depressive disorder, MDD, are 
5.3% and 13.3%, respectively) (Blazer DG, 2000; Hasin et al., 2005). 
Major depression is twice as common in women as in men (Murphy 
et al., 2000; Kessler et al., 1994) and its risk increases 1.5 to 3.0 
times if the illness is present in a first-degree relative as compared 
with no such illness in a first-degree relative (Bland et al., 1997; 
Sadovnick et al., 1994). The association between age and onset is 
debated: it has been suggested that the highest rates of first onset of 
depression occur among young adults (aged 12 to 24) and lower rates 
among people 65 years of age or more (Patten, 2000). Depression is 
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the leading cause of disability worldwide (World Health 
Organization, 1996) and is associated with significant morbidity and 
mortality (Keller et al., 1998; Wells et al., 1989).  Depression is 
correlated with an increased number of suicide attempts and 
increased lethality (Bostwick et al., 2000; Soloff et al., 2000). 
Suicide accounts for almost 2% of the world’s deaths (World Health 
Organization Health Systems, 2000). In most of the developed world, 
suicide is among the top 10 leading causes of death for individuals of 
all ages, and is the third leading cause of death among adolescents, 
after motor vehicle accidents and homicide (Mao et al., 1990; Mann 
J., 2002).   
Depressive illnesses are associated with poor work productivity; 
according to the World Health Organization Global Burden of  
Disease Study depression is the fourth most costly of all medical 
illnesses worldwide and predicted to rank second by the year 2010 
(Murray and Lopez,1997). 
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The classification of depressive disorders is controversial: in the 
current diagnostic systems, the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV-TR, 2000) and the International 
Classification of Diseases (ICD-10, (WHO, 1992) the model is 
unitarian, with disorders differentiated largely on the basis of 
severity: mild, moderate and severe (Parker, 2000). Another binary 
model, i.e. endogenous/melancholic vs. neurotic/reactive, had been 
proposed earlier: according to the ICD-10 Glossary of Mental 
Disorders (WHO, 1994) endogenous depression (manic-depressive 
psychosis, depressive type) was defined as “an affective psychosis in 
which there is reduced activity and widespread depressed mood, self-
reproachful and hypocondrical delusions, shame and disorders of 
sleep, appetite, sexual desire and capacity. Diurnal variations may be 
marched”. Actually, findings from recent studies suggest that there is 
no clear demarcation between mild, moderate and severe depression, 
pointing toward continuity rather than categories of illness. 
Moreover, it has been observed that depressive symptoms may 
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change over time, fulfilling criteria for major depression, minor 
depression, dysthymia, and subsyndromal states. Finally, recent 
genetic studies seem to confirm that the majority of depressions 
develop from the interaction between genes and life events, while 
“reactive” and “endogenous” depressions appear to occur at a lower 
frequency (Kessing, 2007). The approach of conceptualizing 
depression as an unitary disorder with a single pathophysiology has 
been criticized by several authors (Klein, 1974; Parker, 2000; 
VanPraag, 1993) who advocate the tradition of research addressed to 
validating distinct phenotypes of depression by treatment specificity 
and  longitudinal outcome; four types of depression can be identified: 
a) melancholic (endogenous) depression, with a typical symptom 
profile, psychomotor changes, a comparatively lower rate of placebo 
response, and no clear evidence of response to the psychotherapies 
(Klerman, 1971; Paykel, 1971; Thase and Friedman, 1999); b) 
psychotic depression, with additional delusions or hallucinations; c) 
anxious (neurotic) depression, with associated symptoms of anxiety 
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and particular personality or temperamental variables (Winokur, 
1985); and d) atypical depression, defined by reactivity of mood, 
reversed neurovegetative symptoms and interpersonal sensitivity to 
rejection (Liebowitz and Klein, 1979). 
Several correlates for a worse outcome following an episode of 
major depression have been taken into account: socio-demographic 
characteristics (such as non-Caucasian ethnicity, female gender, 
older age, worse education, loneliness, retirement and financial 
problems) (Trivedi et al., 2006; Cohen et al., 2006), and clinical 
variables (including depression subtypes: atypical, psychotic and 
bipolar depression, comorbidity with anxiety disorders, in particular 
panic disorder, obsessive-compulsive and post-traumatic stress 
disorders, alcohol and substance use/dependence disorders, presence 
of personality disorders, and medical comorbidity, such as 
hypothyroidism, stroke, diabetes, coronary artery disease, 
Parkinson’s disease, immunodeficiency, cancer and chronic pain) 
(Keller et al., 1986; Paykel et al., 1973; Alexopoulus et al., 2001; 
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Liebowitz et al., 1988; Charney and Nelson, 1981; Kupfer et al., 
2000; Frank et al., 2000, 2002; Trivedi et al., 2006; DeBattista and 
Mueller, 2001; Nunes et al., 1996; O’Reardon and Amsterdam, 
2001). 
Major depressive episodes are characteristic of  both unipolar 
depressive and bipolar disorder. Diagnostic criteria rely on clinical 
features to distinguish between the two diagnoses. However initial 
misdiagnosis is common (Ghaemi et al., 1999; Ghaemi et al., 2000; 
Hirschfeld et al., 2003), and delayed or inappropriate treatment can 
be associated with consequences, including switching into mania, 
precipitation of a mixed state, more frequent mood episodes, or 
poorer outcome in general (Altshuler et al., 1995; Wehr et al., 1987; 
Goldberg et al., 2002).  Therefore, distinguishing patients with major 
depressive disorder from patients with bipolar disorder in a 
depressive episode is of profound clinical importance and a number 
of studies have attempted that. 
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From a clinical point of view, it has been suggested that bipolar 
depression differs from unipolar depression because it is more 
characterized by behavioral symptoms such as hypersomnia, lethargy 
and apathy, higher rates of suicide attempts, more psychomotor 
retardation, hypersomnia and psychotic symptoms, in comparison to 
the pessimistic thoughts and feelings of worthlessness characterizing 
unipolar depression (Mitchell and Malhi, 2004; Potter, 1998). 
Compared with patients with major depressive disorder, those with 
bipolar depression are more likely to have an earlier age of onset (the 
lifetime risk of bipolar disorder is at least twice as high for those who 
develop recurrent depression before age 20) and a family history of 
bipolar disorder or mania (Goodwin and Jamison, 1990, 2007; 
Akiskal et al., 1983; Winokur et al., 1995). 
In bipolar depression, a greater prevalence of atypical features or 
reverse neurovegetative symptoms, such as hypersomnia or 
hyperphagia, was reported by most studies (Akiskal et al., 1983; 
Perugi et al., 1998; Benazzi F, 1999; Benazzi F., 2003) . Likewise, a 
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greater prevalence of melancholic symptoms among bipolar 
depressed patients was identified in several reports (Mitchell et el., 
2001; Parker et al., 2000). Finally, irritability (Benazzi et al., 2004; 
Deckersbach et al., 2004), anger (Perlis et al., 2004; Mammen et al., 
2004), subthreshold mixed symptoms, such as overactivity (Benazzi 
F., 2003), and psychosis (Akiskal, 1995; Mitchell et al., 2001) have 
also been associated with bipolar depression.  It has been suggested 
that unrecognized bipolar disorder may be common among patients 
with a history of poor response to antidepressant therapy (Ghaemi et 
al., 2000). In addition, antidepressant-induced mood switches are 
considered the strongest indicator of bipolarity among patients with 
“unipolar” depression (Chun and Dunner, 2004) and antidepressants 
may induce adverse outcomes in bipolar disorder such as treatment-
emergent agitation, worsening insomnia, grandiose ideas, or racing 
thoughts despite the persistence of the depressive symptoms 
(Akiskal, 2005). Perlis and collegues (2006) concluded that bipolar 
depression and major depressive disorder exhibit subtle differences 
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in presentation, which may help guide the initial diagnosis. In 
particular, bipolar depression was associated with family history of 
bipolar disorder, an earlier age at onset, a greater previous number of 
depressive episodes, and , individual symptoms (particularly those 
related to anxiety, both somatic and cognitive). Fears were more 
common in patients with bipolar disorder, whereas sadness, 
insomnia, intellectual (cognitive), somatic (muscular), respiratory, 
genitourinary complaints, and depressed behavior were more 
common in patients with unipolar depression.  
Major depressive episodes and depressive symptoms burden bipolar 
patients more than any other mood state: results show that time spent 
in episodes of major depression cover about 31.9% and 50.3% of 
weeks for bipolar I and bipolar II, respectively, while patients of both 
groups spend only about 8.9% and 1.3% in manic or hypomanic 
states, respectively (Judd et al., 2002; 2008). Symptoms of 
depression in bipolar disorder may cause more disruption than 
mania, involving a greater disability and economic burden (Bowden 
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and Krishnan, 2004; Mitchell and Malhi, 2004) and risk for suicide 
attempts and completed suicide (estimated rates of suicide in bipolar 
disorder are around 15%) (Simpson and Jamison, 1999).  
Actually, a dimensional construct for mood disorders has been 
suggested as an alternative to the DSM categorical approach 
(Goodwin and Jamison, 1990; Akiskal, 1996; Dunner, 2003). This 
classification, referred to as bipolar spectrum disorder, is inspired by 
an analogy from general medicine, such as hypertension, that can 
also be viewed along a continuum. The hypothesis of the bipolar 
spectrum is that less conventional forms of bipolar illness may exist 
outside of classical manic-depressive illness or type I bipolar 
disorder (Akiskal, 1996; Cassano et al., 1999; Ghaemi et al., 2002; 
Katzow et al., 2003; Angst and Cassano, 2004). These authors 
advocate the Kraepelinian concept of manic-depressive illness whose 
broad scheme included not only the DSM-IV categories of bipolar 
disorder but also much of the large terrain of recurrent major 
depressions (Akiskal & Pinto, 1999). 
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Neurotrophins and Brain-Derived Neurotrophic Factor 
 
Neurotrophins are a family of regulatory factors, structurally and 
functionally homologous, that mediate the differentiation and 
survival of peripheral and central neurons, as well as the modulation 
of synaptic plasticity (Patapoutian and Reichardt 2001). The 
neurotrophin family includes nerve growth factor (NGF), Brain 
Derived Neurotrophic Factor (BDNF), Neurotrophins (NT) 3, NT4/5 
and NT6 (Patapoutian and Reichardt 2001). These various proteins 
are related in terms of sequence homology and receptor specificity. 
They bind and activate specific receptor tyrosine kinases belonging 
to the Trk family of receptors, including TrkA, TrkB, and TrkC, and 
a pan-neurotrophin receptor P75 (Patapoutian and Reichardt 2001). 
Neurotrophins can be secreted constitutively or transiently, and often 
in an activity-dependent manner. Recent observations support a 
model wherein neurotrophins are secreted locally from the dendrites 
and generally act retrogradely at presynaptic terminals to induce 
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long-lasting modifications (Poo, 2001). In addition to their classical 
roles in neuronal differentiation and survival NTs have also been 
implicated in axon pathfinding and synaptic plasticity (Thoenen, 
1995). NTs were shown to increase the length and complexity of the 
dendritic trees in cortical neurons (McAllister et al., 1995), however, 
this effect could be abolished if spiking, synaptic transmission, or L 
type Ca++ channels were blocked (Mc Allister et al., 1996). The NT 
hypothesis proposes that repetitive neuronal activity enhances the 
expression, secretion and/or actions of neurotrophins at the synapse 
to modify synaptic transmission and connectivity, and thus provides 
a connection between neuronal activity and synaptic plasticity. NTs 
can play either an instructive or permissive role in activity-dependent 
synaptic modification of developing and adult brains. In the 
instructive role, modification is a consequence of NTs acting at the 
synapse to directly modify presynaptic transmitter release, 
postsynaptic sensitivity or synaptic morphology, thus leading to a 
persistent synaptic modification. In the permissive role, modification 
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is induced by other factors that are associated with neuronal activity, 
whereas NTs carry out housekeeping functions that are necessary for 
the modification of the synapse. Within the neurotrophin family, 
BDNF is a potent physiological survival factor that is recognized as 
playing an important role in the survival, differentiation, and 
outgrowth of select peripheral and central neurons during 
development and in adulthood (Schinder et al., 2000). It is the most 
widely distributed trophic factor in the brain and participates in 
plasticity mechanisms such as long-term   potentiation, learning, and 
memory (Schinder et al., 2000). The cellular actions of BDNF are 
mediated through two types of receptors: - a high-affinity tyrosine 
receptor kinase (TrkB) and - a low-affinity pan neurotrophin receptor 
(P75). BDNF also has a number of much more acute effects on 
synaptic plasticity and neurotrasmitters release and it facilitates the 
release of glutamate, γ-aminobutyric acid (GABA), dopamine, and 
serotonin (Goggi et al., 2002; Schinder et al., 2000). It is noteworthy 
that although endogenous neurotrophic factors have traditionally 
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been viewed as increasing cell survival by providing necessary 
trophic support, it is now clear that their survival-promoting effects 
are mediated in large part by an inhibition of cell death cascades 
(Riccio et al., 1999). Increasing evidence suggest that neurotrophic 
factors inhibit cell death cascades by activating the mitogen activated 
protein (MAP) kinase signalling pathway and the 
phosphotidylinositol-3 kinase (PI-3K)/Akt pathway. BDNF is best 
known for its long-term neurotrophic and neuroprotective effects, 
which may be very important for its putative role in the 
pathophysiology and treatment of mood disorders. BDNF mRNA is 
synthesized not only in neurons but also in many other peripheral 
tissues and organs as well as aortic wall, endothelium, heart, kidneys, 
submaxillary glands, ovaries, dorsal ganglia, muscles and lungs 
(experimental evidence in rats) (Fujimura et al., 2002). There BDNF 
is released by target cells of neurons and acts like a surviving 
promoter on neurons themselves. About ten years ago Rosenfeld and 
colleagues found BDNF in blood too (Rosenfeld et al., l995). BDNF 
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levels are about ten times higher in serum than in plasma, perhaps 
since platelets release a big amount of BDNF when they activate. 
Indeed platelets aren’t able to produce BDNF, but they get it from 
plasma through a mechanism we still ignore (Fujimura et al., 2002). 
Plasmatic BDNF is likely produced by endothelium, smooth muscle, 
activated macrophages and lymphocytes. Authors have contrasting 
opinions about BDNF crossing haemato-encephalic barrier (Pan et 
al., 1998) so that it is not clear if central neurons and glia actually 
influence haematic BDNF concentration. However other peripheral 
growth factor like VEGF and IGF-1 can enter in the brain (Pan et al., 
1998): likewise BDNF could do, influencing neurogenesis and CNS 
function. Moreover, we still don’t know the role of platelets BDNF: 
probably it has a specific function during tissue traumas, nerve 
lesions and haemorrhages. In fact when activated platelets release 
BDNF, it could likely play a role in inflammation and smooth muscle 
and cellular proliferation. 
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Neurobiological mechanisms in major depressive disorder:  the 
role of BDNF 
 
While monoaminergic hypotheses of psychopathology remain 
popular, there has been growing interest in the role of neurotrophins 
in neuropsychiatric disorders. 
Several lines of evidence suggest that BDNF, one of the major 
neurotrophic factors, plays an important role in the maintenance and 
survival of neurons and in synaptic plasticity (Dwivedi Y., 2009). 
Many pre-clinical and clinical studies have led to the proposal of the 
“neurotrophin hypothesis of depression”, which suggests that stress 
and depression is associated with decreased expression of BDNF and 
that antidepressants alleviate depressive behavior by increasing its 
level (Duman et al., 2000; Duman RS, 2002). The role of BDNF may 
be crucial in the pathophysiology of depression and in the 
mechanism of action of antidepressants because it is involved in 
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synaptic plasticity and, as earlier mentioned, compromised synaptic 
and structural plasticity have been shown to be associated with 
depression. These observations demonstrate that depression may be 
associated with the inability of neural systems to exhibit adaptive 
plasticity; however, despite the devastating impact of depression on 
numerous lives, the precise molecular and cellular nature of events 
that lead to impaired structural and functional plasticity in depression 
remains unclear; there is still a dearth of knowledge concerning the 
mechanisms underlying the pathogenesis in this disorder. Support for 
the neurotrophin hypothesis comes from the majority of post-mortem 
studies in major depressed subjects demonstrating altered brain 
structure, such as reduction in cell number, density, cell body size, 
neuronal and glial density in frontal cortical or hippocampal brain 
areas and decrease in parahippocampal cortex cortical/laminar 
thickness (Altshuler et al., 1990; Rajkowska et al., 1997; Ongur et 
al., 1998; Rosoklija et al., 2000; Cotter et al., 2001; Rajkowska et al., 
2000; Cotter et al., 2002; Miguel- Hidalgo et al., 2002; Rajkowska et 
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al., 2002). These studies are also consistent with reduced 
neurotrophic support in depression. Volume reductions in frontal 
cortex ranging from 7% overall reduction in frontal lobe volume in 
major depression (Coffey et al., 1992) to 48% in the subgenual 
prefrontal cortex (Drevets et al., 1997) have been reported. Several 
studies have examined hippocampal volume in depression. Some 
(MacQueen et al 2003; Sheline,1996) but not all (Vakili et al 2000) 
found significant reductions in hippocampal volumes in depression. 
In most of these studies that assessed depression severity in unipolar 
subjects and used high31 resolution MRI techniques, depression was 
associated with hippocampal volume loss, ranging from 8% to 19%. 
The hippocampus is one of two neurogenic zones in the adult central 
nervous system; the other is the subgranular zone which gives rise to 
neurons in the olfactory bulb. The rate of proliferation and survival 
of newborn neurons in the hippocampus is also dynamically 
regulated up or down by a variety of stimuli (Duman 2004). Stress is 
one of the most robust negative regulators of adult neurogenesis and 
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stressful life experiences can lead to a depressive episode (Kessler, 
1997; Heim and Nemeroff, 2001). An overactive hypothalamus-
pituitary-adrenal axis has been well established in stress. Studies in 
pre-clinical models have shown stress-induced dysregulation of  
BDNF expression. Smith and colleagues (1995) examined for the 
first time the role of stress and demonstrated that immobilization 
stress used for 1 or 7 days (for 2 hours per day) significantly 
decreased BDNF mRNA expression in the hippocampus. This was 
later confirmed by other investigators (Ueyama et al., 1997; Vaidya 
et al., 1997). Similar changes were observed when other types of 
stressors were used. 
Some of the stressors, such as social defeat, decreased BDNF not 
only in hippocampus but also in cortical and subcortical areas of 
mice (Pizarro et al., 2004). Interestingly, it has been shown that 
maternal separation led to depression like behavior in adulthood, 
which was correlated with decreased BDNF expression (Roceri et 
al., 2002). This study suggests that early developmental insult causes 
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depression in later life, which is mediated through abnormalities in 
BDNF-mediated signaling. Several studies have shown that exposure 
of exogenous corticosterone (to mimic the stress effect) also reduces 
BDNF expression in rodent hippocampus, similar to that observed in 
various pre-clinical stress models (Smith et al., 1995; Chao et al., 
1998; Schaaf et al., 1997; Schaaf et al., 1998). When endogenous 
corticosterone was removed by adrenalectomy, the level of BDNF in 
the hippocampus increased (Barbany et al., 1992; Chao et al., 1998). 
On the other hand, dexamethasone replacement to adrenalectomized 
rats restored the level of BDNF to control levels (Barbany et al., 
1992). These studies demonstrate that expression of BDNF is 
regulated via glucocorticoids. Several clinical studies indicate the 
possibility that a subset of patients with depression exhibit 
neuroendocrine changes [glucocorticoid hypersecretion (Sapolsky, 
2000) or a hyperactivity of the hypothalamicpituitary- adrenal (HPA) 
axis (Arborelius et al., 1999)]. Moreover, distinct reduction in 
hippocampal volume are seen in patients with HPA hyperactivity 
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(Sapolsky, 2000). Although the stress-induced changes in the 
hippocampus may not explain the affective sympoms of depression, 
they provide a cellular basis for understanding the structural 
impairments observed in this brain region as well as in other regions 
associated with depression. 
Neuroimaging technology provides unprecedented opportunities for 
elucidating the anatomic correlates of affective disease. 
Neuroimaging studies of major depression have identified 
neurophysiologic abnormalities in multiple areas of the orbital and 
medial prefrontal cortex, the amygdala, and related parts of the 
striatum and thalamus. Dysfunction involving these regions is thus 
hypothesized to play a role in the pathogenesis of depressive 
symptoms. Functional imaging tools such as positron emission 
tomography (PET), single photon emission computed tomography 
(SPECT), and functional magnetic resonance imaging (fMRI) have 
enabled in vivo characterization of neurophysiologic and/or receptor 
pharmacologic correlates of normal and pathologic emotional states, 
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treatment response and resistance, and chronic or recurrent illness. In 
vivo neuroimaging data are beginning to guide postmortem studies 
of mood disorders by delimiting areas where gray matter volume is 
abnormal and characterizing the clinical conditions under which such 
abnormalities are evident (Drevets, 2000). Magnetic resonance 
imaging and computed tomography (CT) studies have shown diffuse 
cortical and subcortical atrophy and ventricular enlargement in late-
life depression (Pantel et al., 1997; Rabins et al., 1991; Rothschild et 
al., 1989; Soares and Mann., 1997). Many studies have found 
decreased volumes of basal ganglia structures in major depression, 
especially in late-onset depression (Greenwald et al., 1997; Husain et 
al., 1991; Krishnan et al., 1992). 
 Thus, a pathological alteration of the neurotrophic factor system 
may not only lead to defects in neural maintenance and regeneration 
and, therefore, structural abnormalities in the brain, but may also 
reduce neural plasticity and, therefore, impair the individual’s ability 
to adapt to crisis situations. 
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BDNF response in depressed patients before and after treatment: 
clinical studies 
 
Several evidences suggest an important role of BDNF in the 
pathophysiology of mood disorders (Duman et al., 1997; Duman RS, 
2004; Post RM, 2007; Stein et al., 2008). Postmortem studies showed 
that the expression of BDNF is increased  in the brain of depressed 
subjects treated with antidepressants compared with those who were 
untreated (Chen et al., 2001). Recently, many studies have attempted 
to examine the level of BDNF in serum or platelets of depressed 
subjects with and without antidepressant treatment. Although the 
significance of measurement of BDNF in blood cells is unclear, it 
was demonstrated that BDNF may cross the blood-brain barrier and 
that platelet BDNF shows similar changes postnately similar to the 
brain (Karege et al., 2002), suggesting that there are parallel changes 
in the blood and brain levels of BDNF. Specifically, decreased serum 
and plasma BDNF levels have been reported in major depressive 
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disorder (MDD) patients than in normal control subjects (Gonul et 
al., 2003; Karege et al., 2005; Huang et al., 2007; Piccinni et al., 
2008; Sen et al., 2008). Karege and colleagues (2002) were the first 
to found that BDNF level in the serum of depressed subjects was 
significantly lower compared with healthy controls. This decrease 
was negatively correlated with the severity of depression. Recently, 
the same group of investigators showed that the reduced levels of 
serum BDNF in depressed patients is related to release mechanisms 
of BDNF because no change was found in the level of BDNF in 
blood, but serum and platelet BDNF were decreased in depressed 
patients (Karege et al., 2005). Other studies have begun to explore 
serum BDNF through the comparison of levels in depressed patients 
before and after pharmacological antidepressant treatment. Some 
studies have found decreases in serum BDNF level in depressed 
patients and a significant difference after antidepressant treatment 
(Gonul et al., 2005; Piccinni et al., 2008). On the other hand, 
Matrisciano et al., (2009)  found that serum BDNF level was lower at 
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baseline in depressed patients compared to healthy subjects and that 
sertraline increased BDNF level after 5 weeks and 6 months, 
whereas escitalopram increased BDNF level only after 6 months. 
Venalfaxine did not change the level of BDNF. Moreover there was 
a negative correlation between increase in BDNF level and decrease 
in Hamilton Depression Rating Scale score. Similarly, increases in 
serum BDNF level by amitriptyline after 36 days, paroxetine after 4 
or 8 weeks, or venalfaxine after 12 weeks of treatment to depressed 
patients were reported (Aydemir et al., 2005; Yoshimura et al., 2007; 
Hellweg et al., 2008). Several studies have reported an increase in 
serum BDNF level in depressed patients not only after antidepressant 
treatment but also by vagus nerve stimulation, repetitive transcranial 
magnetic stimulation (Lang et al., 2006) or electroconvulsive therapy 
(Bocchio Chiavetto et al., 2006). In a recent meta-analysis, Brunoni 
et al., (2008) and Sen et al., (2008) concluded that BDNF levels are 
lower in depressed patients than healthy controls and that BDNF 
levels are significantly higher after antidepressant treatment. 
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Generally, the intake psychotropic drugs by patients with mood 
disorders has been considered a source of potential bias (de Oliveira 
et al., 2009), as some evidences suggest that antidepressants 
normalize serum BDNF levels (Huang et al., 2008; Gonul et al., 
2003), although opposite data are also available (Yoshimura et al., 
2007). Recently, decreased BDNF levels have been reported in 
euthymic patients with unipolar and bipolar depression, irrespective 
of the medications (Monteleone et al., 2008).  
Overall, these findings provide strong evidence of modulation in 
BDNF in depression and in response to antidepressants. 
The current treatment model suggests that long-term, therapeutic 
action of antidepressants is mediated by intracellular targets 
following noradrenergic (NE) or serotonergic (5-HT) stimulation, 
enhancing by antidepressant medications themselves. A major signal 
transduction pathway mediating 5-HT and NE action utilizes cyclic 
adenosine monophosphate (cAMP). Recent evidence indicates that 
BDNF up-regulation via antidepressant administration occurs 
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through the cAMP signal transduction pathway and the transcription 
factor, cAMP response element binding protein (CREB) (Nibuja et 
al., 1996; Jensen et al., 2000). Taken together, these findings provide 
strong evidence that increased expression of BDNF is a downstream 
effect of increased 5-HT/NE neurotrasmission, and that this may be 
responsible for the therapeutic effect of antidepressants. Different 
types of antidepressants may exert their therapeutic effects through a 
chronic, but not an acute, administration suggesting that the 
regulation of long-term gene expression through intracellular 
signaling pathways may underlie some of their mechanism of action. 
The intracellular signaling pathways modulate neuronal function, 
increasing neurogenesis and mediating the long-term persistent 
adaptations that serve as a form of drug-induced neural plasticity. 
Chronic administration of antidepressants causes morphological 
changes in neurons and could explain how drugs mediate persistent 
structural plasticity in the brain (D’sa and Duman,  2002). 
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Neurobiological and clinical implications of BDNF in mood 
disorders: the experience conducted at the University of Pisa 
 
Studies conducted by our research group for almost four years have 
been attending to investigate the relationships between affective 
disorders and BDNF from both neurobiological and clinical point of 
view. Our recent report (Piccinni et al., 2008)  aimed to investigate 
the possible relationships between depressive symptoms and serum 
and/or plasma BDNF levels during 1 year of antidepressant 
treatment. We observed that untreated depressed patients, diagnosed 
according to Diagnostic and Statistical Manual for Mental Disorders 
(DSM-IV-TR, American Psychiatric Association, 2000) using the 
Mini International Neuropsychiatric Interview (MINI), showed 
reduced baseline serum and plasma BDNF levels, as compared with 
control subjects. The clinical improvement assessed using the 
Hamilton Rating Scale for Depression (HDRS; Hamilton, 1960) and 
the Montgomery–Asberg Depression Rating Scale (MADRS; 
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Montgomery and Asberg, 1979), paralleled the normalization of 
plasma BDNF after 1 month of treatment, while, at every assessment 
time, patients' serum BDNF levels were lower than those of control 
subjects. We hypothesized that serum BDNF might represent a non-
specific trait marker of depression. In another report (Piccinni et al., 
2008) we evaluated the presence of a possible diurnal rhythm of 
plasma and serum BDNF concentrations in healthy subjects of both 
sexes; in a smaller subsample of women, the measurement of diurnal 
plasma and serum BDNF levels was compared between two phases 
of the menstrual cycle. We found statistically significant diurnal 
variation in plasma BDNF level in men, with the peak at 08:00 h and 
nadir at 22:00 h. At this time, the plasma BDNF concentration of 
men was significantly lower than that of women. However, no 
diurnal variation was found either in plasma BDNF of women, in 
either the follicular or luteal phases of the menstrual cycle, or in 
serum BDNF level both in men and women. We concluded that these 
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findings may support the concept of rhythmic variation in plasma 
BDNF regulation that seems to be gender-related. 
We conducted a recent study evaluating whether the clinical course 
of medication-resistant depressed patients following a course of ECT 
might be associated with changes of plasma BDNF concentrations 
(Piccinni et al., 2009). Our findings showed that at T0 (baseline) 
plasma BDNF levels of patients were significantly lower than those 
of control subjects, and that at T2 (after ECT) were significantly 
increased in parallel with the decrease of the Hamilton Rating Scale 
for Depression (HRSD) total score. However, only remitter patients 
who showed higher baseline BDNF levels than non-remitters reached 
normalized BDNF levels after ECT. These findings would suggest 
the potential usefulness of baseline plasma BDNF levels as 
predictors of response to ECT in treatment-resistant depressed 
patients. 
We recently aimed to study the relationship between traumatic 
stressful events and BDNF in patients suffering from Post-Traumatic 
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Stress Disorder (PTSD). 14 clinically diagnosed PTSD participants 
were recruited and compared with 14 healthy controls in terms of 
plasma levels of BDNF and PTSD symptoms. Results indicated that 
patients with PTSD had significantly lower BDNF levels than 
control subjects; moreover, subjects who experienced other types of 
trauma than complicated grief and patients who experienced more 
lifetime traumas showed significantly lower plasma BDNF levels 
than controls. Time from trauma and other clinical characteristics of 
PTSD symptomatology, such as the number of intrusion and 
avoidance symptoms, seemed not to be related to BDNF levels. Our 
findings suggest that decrease in BDNF levels may be involved in 
the neurobiology of PTSD, but further prospective studies are 
required to confirm this observation (Dell’Osso et al., 2009). 
The dimension of attachment, which may be related to the 
development of affective disorders, has been investigated in another 
study in relation to BDNF levels. Twenty-four healthy volunteers 
were included in the study. The romantic attachment was assessed by 
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means of the Italian version of the “Experiences in Close 
Relationship” (ECR) questionnaire. Women showed a higher score 
of the ECR anxiety scale than men, as well as a significant and 
negative correlation between the ECR avoidance scale and BDNF 
plasma levels. Again in women, significant and negative correlations 
were observed between BDNF levels and the following ECR items: 
the #1 and the #13; on the contrary, positive correlations were 
measured with the #20, #31 and #33. Men showed only one negative 
correlation with the ECR item #6. According to our observations, 
BDNF plasma levels and romantic attachment seem to be related, but 
differently in the two sexes. BDNF would play a role in promoting 
social relationships through a specific effect to diminish avoidance 
and fear of the other, while reducing social stress responses mainly in 
women, and perhaps, through hormonal and genotype interactions 
(Marazziti et al., 2009). 
Finally we conducted a recent study aiming to analyze BDNF plasma 
levels in unipolar and bipolar depressed patients, and to explore the 
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possible relationships between the biological parameter and the 
clinical features in subjects with unipolar versus bipolar depression. 
Compared to healthy control subjects, plasma BDNF concentrations 
were significantly reduced in both unipolar and bipolar depressed 
patients with no significant difference among them. Our findings 
revealed significant  and negative correlations in the total sample 
between BDNF levels and the HRSD total scores, the retardation 
factor scores and CGI “severity of illness” item scores.  When the 
same analyses were repeated in each group separately, the previous 
findings were confirmed only in the bipolar depressed patients. In 
conclusion, our results show that lower BDNF levels may be related 
to both severity of depression and retardation symptom in bipolar 
depression. Further studies need to ascertain whether and how BDNF 
levels may be associated with any psychopathological dimensions of 
depressive state and be used as biological marker to differentiate 
bipolar from unipolar depression (Dell’Osso et al., submitted to 
Giornale Italiano di Psicopatologia). 
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AIMS OF THE STUDY 
 
In view of the paucity of information and controversies about the 
relationship between BDNF levels and characteristics of depression, 
the aim of the present study was to assess plasma BDNF levels in 
depressed patients well-characterized from the clinical point of view, 
and to explore the possible relationships between the biological 
parameter and illness features and symptoms. In fact, BDNF changes 
in depression have been linked to clinical characteristics, such as 
severity of the illness (Shimizu et al., 2003), or presence of psychotic 
symptoms (Lee et al., 2007). However, the ensuing findings 
emerging from the different studies are not easily comparable 
because the BDNF was evaluated in plasma or serum, and the 
patients’ samples were heterogenous. 
We looked for possible correlations between plasma BDNF levels 
and socio-demographic and clinical characteristics of the sample, 
such as age, gender, presence of psychotic or dissociative symptoms, 
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age of onset, severity of affective symptoms rated by standardized 
clinical assessment instrument, recurrence and Hamilton Rating 
Scale for Depression (HRSD21) factors singularly evaluated 
(anxiety/somatization, weight, cognitive disturbance, diurnal 
variation, retardation, sleep disturbance). 
Finally, we evaluated differences in socio-demographic, clinical 
variables and plasma BDNF values between men and women. 
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METHODS 
 
Subjects 
Thirty in- and outpatients of both sexes (19 women and 11 men, age 
between 22 and 65 years, mean ± SD: 45.9 ± 14.8 years) were 
recruited at the Dipartimento di Psichiatria, Neurobiologia, 
Farmacologia e Biotecnologie, University of Pisa, between 
September 2006 and December 2008, and consecutively enrolled in 
the study. All patients were suffering from a current major 
depressive episode, single episode (6) or recurrent (24), diagnosed 
according to the Diagnostic and Statistical Manual for Mental 
Disorders criteria (APA, 2000). The diagnosis was confirmed by 
means of the Mini International Neuropsychiatric Interview (MINI) 
(Sheehan et al., 1998). Exclusion criteria included the presence of 
organic brain disorder, substance abuse, pregnancy or any severe or 
chronic physical illness. Patients were either medication-naïve (n=6) 
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or medication-free approximately for 1 year (n=19) or at least for 2 
weeks (n=5). 
No woman took contraceptive drugs; 6 women were in menopause. 
Blood from all the fertile women was drawn in the mid-follicular 
phase. 
Fifteen healthy subjects (3 men and 12 women, mean age±SD: 
46.9±9.2 years), with no history of past or current chronic physical or 
mental disorders and not taking regular medications, were recruited 
as the control group. 
All patients provided informed written consent to the study which 
was approved by the Ethics Committee of the University of Pisa in 
accordance with the Declaration of Helsinki (1996) and with the 
guidelines of the Good Clinical Practice (1995). 
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Clinical assessment 
The diagnosis of  major depression was confirmed by the 
administration of M.I.N.I. version 5.0.1. (Sheehan et al., 1998). The 
MINI is a brief structured interview designed to identify the major 
Axis I psychiatric disorders in the DSM-IV and ICD-10. In 
validation and reliability studies, the MINI was compared with the 
Structured Clinical Interview for DSM-III-R, Patient Version, and 
found to have acceptably high validation and reliability scores 
(Lecrubier et al 1997). The MINI, however, can be administered in a 
much shorter period and can be used by clinicians after a brief 
training session. The interview is divided into modules, each 
corresponding to a diagnostic category. At the end of each module, 
clinicians are able to determine whether the diagnostic criteria are 
met for a particular category. 
The severity of depression was assessed by means of the 21-item 
Hamilton Rating Scale for Depression (HRSD21) (Hamilton M, 1960) 
and the Clinical Global Impressions – Severity of Illness scale (CGI-
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S) (Guy W., 1976). Patients had a HRSD total score of 24.4 ± 5.7 
and a CGI score of 4.8 ± 0.8. 
 
BDNF Assay  
Ten ml of venous blood were drawn in the morning, between 8:00 
and 9:00 a.m., following an overnight fast, into EDTA-coated tubes 
that were kept on ice, centrifugated at 2000xg for 10 minutes at 4°C 
and refrigerated at -20°C. To measure the amount of total BDNF, 
acidification and subsequent neutralization of the samples were 
followed before proceeding with the enzyme-linked immunosorbent 
assay (ELISA) protocol, according to manufacturer’s instruction 
(Promega, Wallisellen, Switzerland). Ninety-six-well plates were 
coated with anti-BDNF monoclonal antibody and incubated at 4°C 
for 18 hours. The plates were incubated in a blocking buffer for 1 
hour at room temperature, then samples were added. The samples 
and BDNF standards were maintained at room temperature under 
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shaking for 2 hours, followed by washing with the appropriate 
buffer. The plates were successively incubated with anti-human 
BDNF polyclonal antibody at room temperature for 2 hours, washed 
and incubated with anti-IgG antibody conjugated to horseradish 
peroxidase for 1 hour at room temperature. The plates were 
incubated in peroxidase substrate and tetramethylbenzidine solution 
to produce a colour reaction. The reaction was stopped with 1 M 
HCl. The absorbance at 450 nm was measured with a microplate 
reader (Model 550, Bio Rad Laboratories) to determine BDNF 
values that are expressed as pg/ml. 
 
Statistical analyses 
Since BDNF levels and HRSD scores were not normally distributed, 
non-parametric tests were used. To compare these variables amongst 
multiple or two independent samples, the Kruskal-Wallis and the 
Mann-Whitney tests were used, respectively. To analyze the 
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relationhips between variables the Spearman’s coefficient was 
computed. A p-value of <.05 was judged as statistically significant. 
All analyses were carried out using the SPSS version 14.0, by means 
of personal computer programmes. 
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RESULTS 
 
Table 1 shows the socio-demographic, clinical variables and plasma 
BDNF values of the sample. 
No significant difference was detected in age, plasma BDNF levels, 
HRSD total and factors scores between men and women. Only the 
difference in Retardation factor scores with men reporting higher 
values approached significance (p= 0.062). Compared to healthy 
control subjects, plasma BDNF concentrations were significantly 
reduced in depressed patients (p= .003). Significant and negative 
correlations were observed between BDNF levels (mean ± SD, 
pg/ml) and the HRSD total or Retardation factor scores (r=-0.483, 
p=0.007 and r=-0.397, p=0.030, respectively) (fig. 1 and 2). 
Moreover, after categorizing the sample on the basis of 75° 
percentile of the HRSD Sleep disturbances factor score (equal to 1), 
significant lower BDNF levels were observed in those patients (n=6) 
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with the highest HRSD Sleep disturbances factor scores 
(1231.62±629.79 vs 2866.62±1628.66, Z=-2.826, p=0.005) (table 2). 
When the patients were distinguished in those with and those without 
dissociative symptoms, patients (n=13) of the first group showed 
significantly lower plasma BDNF levels than those of the second 
(1910.97±1054.47 vs 3020.35±1827.13; Z=-2.009, p=0.045). 
As for as the CGI is concerned, BDNF levels differed significantly 
amongst groups [“moderately ill” (score=4 of the CGI “severity of 
illness” item) (n=13): 2780.54±1353.42; “markedly ill” (score=5) 
(n=10): 2573.86±2155.80; “severely ill” (score=6) (n=7): 
1213.23±158.68; X
2
=4.350; p=0.023]. Between groups comparisons 
showed that the “severely ill” patients scored significantly lower than 
the “moderately ill” (score=4) ones (Z=-2.656, p=0.008). 
Furthermore, the 24 patients with recurrent episodes of depression 
showed significantly lower BDNF levels than those with single 
episode (2112.49±1168.59 vs 4248.14±2122.38, Z=-2.489, p=0.013) 
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(tab. 2). Finally, no correlation was observed between plasma BDNF 
levels and presence of psychosis or age of onset. 
Given that our sample was composed by some patients with a shorter 
period of drug washout (at least for 2 weeks, n=5), we further 
replicated our analyses while eliminating these subjects from the 
total sample. In this case, too, HRSD total and Retardation factor 
scores showed the same significant negative correlations with BDNF 
levels (r=-0.509, p=0.007 and r=-0.384, p=0.048, respectively). 
Moreover, highest HRSD Sleep disturbances factor scores were 
associated with lower BDNF levels (1187.62±306.57 vs 
3402.75±1697.90, Z=-3.723, p=0.000). In addition, patients with 
dissociative symptoms (n=12) showed significantly lower plasma 
BDNF levels than those without them (1737.67±887.19 vs 
3065.63±2020.19; Z=-1.986, p=0.047). Finally, BDNF levels 
differed significantly amongst CGI scoring groups [“moderately ill” 
(n=8): 3030.90±1309.31; “markedly ill” (n=10): 2573.86±2155.80; 
“severely ill” (n=7): 1213.23±158.68; X
2
=7.096; p=0.029]; 
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difference in BDNF levels between patients with recurrent episodes 
of depression (n=20) vs. those with a single episode were close to 
significance (Z=-1.835; p=0.067). 
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DISCUSSION AND CONCLUSIONS 
 
The results of the present study led to different findings. First, 
we observed significant negative correlations between the severity of 
illness, as rated by the HRSD total score, and plasma BDNF levels, 
that is to say, the more severe the patient, the lower the biological 
parameter. This finding is consistent with previous data gathered in 
drug-free depressed patients (Shimizu et al., 2003; Gonul et al., 
2005), but at variance with others (Lee et al., 2007). The link 
between BDNF and depression is hence supported by our 
observation that the plasma levels of the “severely ill” patients 
resulted significantly lower than those of the “moderately ill” ones.  
Although several evidences suggest an important role of 
BDNF in the pathophysiology of mood disorders and response to 
antidepressant medications (Shimizu et al., 2003; Aydemir et al., 
2005; Gervasoni et al., 2005; Gonul et al., 2005; Lee et al., 2007; 
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Marano et al., 2007; Huang et al., 2008; Piccinni et al., 2008; 
Matrisciano et al., 2009; Piccinni et al., 2009), conflicting results 
have been gathered on this topic. For example, a recent study 
reported no significant difference in peripheral BDNF concentrations 
comparing BDNF levels in depressed patients before and after 
pharmacological antidepressant treatment (Yoshimura et al., 2007). 
Moreover, there is little information about the source of BDNF in the 
blood and studies about the relationship between brain and blood 
BDNF levels have led to conflicting findings (Karege et al., 2002; 
Elfving et al., 2009). Studies of BDNF uptake or transport across the 
blood brain barrier have been mixed and additional data are needed 
to support the existence of an active transport system for uptake of 
BDNF into the brain (Sen et al., 2008). 
 Second, even the HRSD “Retardation” factor scores correlated 
negatively with BDNF levels. According to us, this is an intriguing 
finding, because psychomotor retardation is considered a core 
symptom of depression and has been linked generally to the severity 
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of illness (Benazzi F., 2002), or to melancholia (Parker G., 2000). 
From a neurobiological point of view, it has been shown that some 
phenotypes of depressive patients, including the melancholic, are 
characterized by a more marked disturbance of the hypothalamic-
pituitary adrenal (HPA) axis, as compared with the others ( Pintor et 
al., 2007; Pintor et al., 2009). The influence of corticosteroid 
hormones on BDNF expression has been showed in preclinical 
studies which reported how cortisol may exert a downregulation on 
BDNF synthesis in the central nervous system (Schaff et al., 2000).  
Third, lower BDNF plasma levels were found in those patients 
with the most severe sleep disturbance. Links between sleep 
disturbances and depression are known all along: about three 
quarters of depressed patients complain of sleeplessness that 
provokes subjective distress, impairment of quality of life, and 
represents a strong risk factor for suicide and recurrence (Nutt et al., 
2008). Moreover a HPA overdrive, as observed especially in 
depressed patients with melancholic features, appears to be related to 
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dysregulations of sleep (Antonijevic I., 2008). Interestingly, a recent 
study in rats suggests a relationship between the synaptic plasticity 
and the homeostasis of sleep, while identifying BDNF as a major 
mediator of this link at the molecular level (Huber et al., 2007).  
Fourth, we found lower BDNF concentrations in patients with 
depersonalization/derealization symptoms: this is consistent with a 
similar observation gathered in patients affected by burn-out, a 
syndrome characterized by chronic stress (Onen Sertoz et al., 2008). 
This finding may represent another indicator of the relationships 
between BDNF and stress systems, as dysregulations of the HPA 
axis has been reported in patients with depersonalization (Simeon et 
al., 2001). 
Fifth, in agreement with a previous study (Lee et al., 2007), 
patients who were suffering from a recurrent episode had 
significantly lower levels of BDNF. It should, however, be 
underlined that the patients with single episode of our sample were 
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not as numerous as those with recurrent episodes, so that the results 
of statistical analysis may not be considered totally reliable.  
This study suffers several limitations that should be 
acknowledged. The most important was that the sample size was 
small, included mainly women and some underwent a short wash-out 
period. Another problem is related to the extent to which blood 
BDNF levels may reflect brain BDNF concentrations. We chose to 
investigate BDNF in plasma, because poor-platelet plasma BDNF 
seems to be minimally affected by the amount of BDNF stored in 
platelets and, therefore, may represent a more reliable and sensitive 
marker of BDNF variations occurring in the brain and 
periphery(Lommatzsch et al., 2005). Nevertheless, plasma BDNF 
has shown high inter-individual variability. It should also be 
mentioned that our absolute plasma BDNF values were higher than 
those observed in recent publications  (Lommatzsch et al., 2005; 
Begliuomini et al., 2008). However, as previously reported (Piccinni 
et al., 2008), we assayed total BDNF in plasma by the acidification 
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and neutralization procedures, while others might have measured the 
amount of the free mature form. Therefore, according to us, different 
methodological procedure might contribute to explain the 
controversial data present in literature (Karege et al., 2005; Palomino 
et al., 2006). The mature form and the precursor form of BDNF play 
different roles in cell survival, synaptic plasticity and cognitive 
functions in health and pathology (Martinowich et al., 2007). In 
animals, recently, we showed that the mature, but not the precursor, 
form of BDNF was significantly increased in the prefrontal cortex of 
rats treated for 14 days with duloxetine at 30 mg/kg/day (Mannari et 
al., 2008). 
The use of medications has been always considered a 
confounding factor in the measurements of BDNF levels in mood 
disorders (de Oliveira et al., 2009). In our study, however, we found 
no difference in a further replication of the analyses by excluding 
patients with 2-weeks washout. Interestingly, decreased BDNF levels 
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have been reported in both treated and untreated euthymic patients 
with unipolar and bipolar (type I and II) (Monteleone et al., 2008). 
In conclusion, our results showed that lower BDNF levels may 
be associated to both recurrence and severity of depression, as well 
as to symptoms suggesting dysregulations of the HPA axis. Further 
studies are needed to elucidate more thoroughly the involvement of 
BDNF in the pathophysiology of symptom patterns or dimensions 
that may well be present in a broad range of neuropsychiatric 
conditions.  
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Table 1 Characteristics of the patients 
 
 
Age (mean ±  SD), years 
 
45.9 ± 14.8 
 
 
Age at onset (mean ±  SD), years 
 
 
31 ± 14 
 
F, M 
 
19 (63.3%), 11 (36,7%) 
 
Psychotic/Non psychotic 
 
8 (26.7%), 22 (73.3%) 
 
HRSD21  (mean ± SD) 
 
24.43 ± 5.78 
 
CGI (mean ± SD) 
 
4.79 ± 0.83 
 
HRSD factor score (mean ± SD) 
 
          Anxiety/Somatization 
          Weight 
          Cognitive disturbance 
          Diurnal variation 
          Retardation 
          Sleep disturbance 
 
 
 
 
1.3 ± 0.35 
0.5 ± 0.73 
0.82 ± 0.50 
0.58 ± 0.63 
1.89 ± 0.78 
0.74 ± 0.47 
 
Plasma BDNF level (mean ± SD, pg/ml) 
 
2539.62 ± 1616.98 
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Table 2 Plasma BDNF levels and clinical features in depressed patients 
 
 
 n BDNF Levels 
(mean ±  SD) 
Z P 
Moderately ill patients (CGI=4) 
 
Severely ill patients (CGI score=6) 
 
13 
 
7 
2780.54 ±1353.42 
 
1213.23 ±158.68 
 
- 2.656 
 
.008 
Low Sleep Disturbance factor score 
 
High Sleep Disturbance factor score 
  
24 
 
6 
2866.62 ±1628.66 
 
1231.62 ± 629.79 
 
- 2.826 
 
.005 
Absence depersonalization/derealization item 
 
Presence depersonalization/derealization item 
17 
 
13 
3020.35 ± 1827.13 
 
1910.97 ± 1054.47 
 
- 2.009 
 
.045 
Single episode 
 
Recurrence 
6 
 
24 
4248.14 ± 2122.38 
 
2112.49 ± 1168.59 
 
 
- 2.489 
 
 
.013 
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FIGURES 
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Figure 1 
Relationship between HRSD total scores and BDNF plasma levels 
 
 
BDNF, Brain-derived neurotrophic factor; HRSD, Hamilton Depression 
Rating Scale 
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Figure 2 
Relationship between HRSD Retardation factor scores and BDNF plasma 
levels 
 
 
BDNF, Brain-derived neurotrophic factor; HRSD, Hamilton Depression 
Rating Scale 
